NASDAQ · APRE
Healthcare · Biotechnology
$0.52
Down-$0.01 (-1.90%)
Updated Nov 4, 2026, 9:07 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · APRE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
APRE closed at $0.52 after 21 trading sessions, down 18.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.4875 | $0.5166 | $0.48 | $0.515 | 64.01K |
| Nov 2, 2026 | $0.50 | $0.5199 | $0.4857 | $0.491 | 89.16K |
| Oct 30, 2026 | $0.4788 | $0.5214 | $0.46 | $0.4846 | 167.61K |
| Oct 29, 2026 | $0.54 | $0.54 | $0.4856 | $0.4936 | 171.06K |
| Oct 28, 2026 | $0.512 | $0.5398 | $0.512 | $0.5378 | 147.5K |
| Oct 27, 2026 | $0.4355 | $0.5356 | $0.429 | $0.513 | 187.91K |
| Oct 26, 2026 | $0.52 | $0.52 | $0.41 | $0.449 | 568.67K |
| Oct 23, 2026 | $0.5267 | $0.5461 | $0.495 | $0.5177 | 89.18K |
| Oct 22, 2026 | $0.5594 | $0.5594 | $0.511 | $0.5416 | 130.06K |
| Oct 21, 2026 | $0.5639 | $0.60 | $0.5106 | $0.5603 | 81.62K |
| Oct 20, 2026 | $0.545 | $0.5674 | $0.5106 | $0.5612 | 366.95K |
| Oct 19, 2026 | $0.603 | $0.6053 | $0.5296 | $0.5323 | 201.07K |
| Oct 16, 2026 | $0.658 | $0.658 | $0.5729 | $0.5842 | 160.1K |
| Oct 15, 2026 | $0.58 | $0.626 | $0.58 | $0.6176 | 66.46K |
| Oct 14, 2026 | $0.6113 | $0.6113 | $0.5821 | $0.583 | 74.39K |
| Oct 13, 2026 | $0.61 | $0.6477 | $0.5931 | $0.60 | 136.92K |
| Oct 12, 2026 | $0.61 | $0.6146 | $0.581 | $0.5931 | 117.52K |
| Oct 9, 2026 | $0.5571 | $0.6069 | $0.5571 | $0.6044 | 70.59K |
| Oct 8, 2026 | $0.6051 | $0.61 | $0.55 | $0.5582 | 239.49K |
| Oct 7, 2026 | $0.6355 | $0.6379 | $0.5758 | $0.605 | 249.9K |
| Oct 6, 2026 | $0.68 | $0.68 | $0.6343 | $0.6355 | 199.17K |
The latest Smart Investors Daily articles mentioning APRE.
Company
Market Activity
Research & News
APRE research
Company profile and research snapshot.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Ladenburg Thalmann | Buy | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Benzinga · Aug 27, 2026
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock increased by
Benzinga · Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APRE.
